Company Description
Adlai Nortye Ltd., a clinical-stage company, together with its subsidiaries, engages in the research and develops pharmaceutical products.
Its product pipeline comprises AN0025, a small molecule EP4 antagonist which is in phase Ib and radiotherapy/chemoradiotherapy combination for the treatment of rectum cancer and esophageal cancer; and phase II trial for patients with moderate to high-risk rectal cancer.
The company also develops AN9025, an oral small molecule pan-RAS(ON) inhibitor, which is in phase 1a clinical trials for the treatment of RAS-mutant cancers, including pancreatic, lung, and colorectal adenocarcinomas; AN4035, a proprietary CEACAM5-targeting antibody drug conjugate designed to deliver potent anti-tumor activity with an improved therapeutic window; and AN8025, a tri-specific antibody fusion protein which is in phase Ia clinical trial to treat advanced tumors.
In addition, it develops AN4005, a small-molecule PD-L1 inhibitor that demonstrates antitumor activity by the blockade of PD-1/PD-L1 interaction which is in phase 1b clinical trial to activate cancer immunity.
Further, the company is involved in technology transfer and consulting services business. Adlai Nortye Ltd. was founded in 2004 and is headquartered in North Brunswick, New Jersey.
| Country | United States |
| Founded | 2004 |
| IPO Date | Sep 29, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 109 |
| CEO | Yang Lu |
Contact Details
Address: New Jersey Biotechnology Dev Ctr, 2nd floor North Brunswick, New Jersey 08902 United States | |
| Phone | 848 230 7430 |
| Website | adlainortye.com |
Stock Details
| Ticker Symbol | ANL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $23.00 |
| CIK Code | 1944552 |
| CUSIP Number | 00704R109 |
| ISIN Number | US00704R1095 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ngai Chiu Tse M.D., Ph.D. | President and Head of Research & Development |
| Dr. Zhiyong Yu Ph.D. | Vice President of Operations |
| Donghui Yang | Chairman of the Greater China Region |
| Dr. Nanhai He Ph.D. | Head of Discovery |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 15, 2026 | SCHEDULE 13G | Filing |
| May 14, 2026 | SCHEDULE 13G/A | Filing |
| Apr 28, 2026 | EFFECT | Notice of Effectiveness |
| Apr 24, 2026 | F-3/A | Filing |
| Apr 23, 2026 | F-3/A | Filing |
| Apr 16, 2026 | 6-K | Report of foreign issuer |
| Apr 10, 2026 | 20-F | Annual and transition report of foreign private issuers |
| Apr 1, 2026 | 6-K | Report of foreign issuer |
| Mar 10, 2026 | F-3 | Filing |
| Feb 12, 2026 | 6-K | Report of foreign issuer |